Abstract | OBJECTIVES: BACKGROUND: METHODS: A total of 172 patients were randomized to daily treatment with placebo, 35 mg, 75 mg, or 125 mg of oral AZ in this dose-ranging pilot study of patients with ICDs. The majority of patients had a history of documented remote myocardial infarction and congestive heart failure New York Heart Association class II or III. RESULTS: The frequency of appropriate shocks and ATP were significantly decreased among AZ-treated patients compared with placebo patients. The incidence of ICD therapies per patient-year among the placebo group was 36, and it was 10, 12, and 9 among 35 mg, 75 mg, and 125 mg AZ patients, respectively (hazard ratio = 0.31, p = 0.0001). Azimilide dihydrochloride was generally well tolerated and did not affect left ventricular ejection fraction or minimal energy requirements for defibrillation or pacing. CONCLUSIONS:
|
Authors | Igor Singer, Hussein Al-Khalidi, Imran Niazi, Patrick Tchou, Tony Simmons, Richard Henthorn, Michael Holroyde, Jose Brum |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 43
Issue 1
Pg. 39-43
(Jan 07 2004)
ISSN: 0735-1097 [Print] United States |
PMID | 14715180
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Arrhythmia Agents
- Hydantoins
- Imidazoles
- Imidazolidines
- Piperazines
- azimilide
|
Topics |
- Aged
- Anti-Arrhythmia Agents
(therapeutic use)
- Defibrillators, Implantable
- Double-Blind Method
- Female
- Humans
- Hydantoins
- Imidazoles
(therapeutic use)
- Imidazolidines
- Male
- Pilot Projects
- Piperazines
(therapeutic use)
- Recurrence
- Tachycardia, Ventricular
(prevention & control, therapy)
|